Coming off a string of deals to discover targets and compounds on its partners’ behalf, Insilico Medicine has launched versions of its platforms that pharmas can use themselves. This year, Insilico Medicine Inc. made its...

MorphoSys’ first marketed therapeutic, Monjuvi, has the makings of a blockbuster, but the company and partner Incyte will need to execute on the drug’s launch and planned label expansions to generate the...

Two months after backing Exscientia in a series B round, Celgene signed a three-year deal with the AI company to discover small molecules for three of Celgene's oncology and autoimmunity programs. Exscientia Ltd. (Oxford, U.K.)...

After spending six years building its artificial intelligence drug discovery platform and working with pharma partners, Exscientia Ltd. aims to use the bulk of the $26 million raised in a series B round to build...

ReGenX granted newco Dimension an exclusive, worldwide license to NAV vector technology and rights to undisclosed, preclinical programs in rare disease indications. Dimension will develop adeno-associated viral (AAV) vector gene therapies for rare diseases, with...

Kymab Ltd. is developing its Kymouse transgenic mouse platform to generate a greater repertoire of human mAbs than it says can be done with competing technologies. With the Wellcome Trust backing the newco, management plans...

Newco Valocor acquired QLT91382 , QLT418 and QLT450 from QLT and received exclusive, worldwide rights to QLT's lemuteporfin. QLT discontinued development of lemuteporfin in 2008 after a Phase I/II trial showed the topical photosensitizer did not...

QLT said it plans to halt development of lemuteporfin to treat acne after an interim review of data from a Phase I/II trial showed the product did not meet an internal therapeutic threshold. In 2006,...

MorphoSys (FSE:MOR) and Novartis (NVS; SWX:NOVN) signed an antibody deal that should fund the biotech's next stages of internal therapeutic development. The agreement, an expansion of a 2004 deal, will give MOR $600 million over...